Phaseline

Companies › Curadel Surgical Innovations

Curadel Surgical Innovations: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nizaracianine Triflutate
Near-infrared fluorescent imaging agent for ureter visualization
–Phase 2Injury of Ureter During Surgery (Disorder)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06101745Nizaracianine TriflutatePhase 2Injury of Ureter During Surgery (Disorder)OtherJul 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Angitia Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.